Drug General Information
Drug ID	D03LQC
Former ID	DIB011808
Drug Name	APD-209
Synonyms	Undisclosed cachexia therapy (oral fixed-dose combination), Acacia
Indication	Cachexia [ICD9: 799.4; ICD10:R64]		Phase 2	[524508]
Company	Acacia Pharma Ltd
Structure		Download 2D MOL
Target and Pathway
Target(s)	Beta-2 adrenergic receptor	Target Info	Agonist	[544329]
KEGG Pathway	Calcium signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Endocytosis
	Adrenergic signaling in cardiomyocytes
	Salivary secretion
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Beta2 adrenergic receptor signaling pathway
Pathway Interaction Database	Arf6 trafficking events
	Arf6 signaling events
Reactome	Adrenoceptors
	G alpha (s) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	GPCRs, Class A Rhodopsin-like
	Vitamin D Receptor Pathway
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 524508	ClinicalTrials.gov (NCT01977443) Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC). U.S. National Institutes of Health.
Ref 544329	Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.